Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

<< Back to News

05/08/18 -- Inflectra for Inpatient Use

Folks,

There are now 3 biosimilar infliximab products (Inflectra, Reflexis, and Ixifi) that have been approved by the FDA in addition to Remicade.  We have only addressed Inflectra thus far.  Currently we are still using Remicade in the outpatient setting due to complicated reimbursement issues.  However, for inpatient use Inflectra is about $500 less per 100 mg vial than Remicade, which means a dose of 5 mg/kg in a 70 kg patient would be about $2,000 less with Inflectra than Remicade. 

Therefore, we should be using Inflectra currently for all INPATIENT infliximab orders instead of Remicade.  Keith will stock a small volume of Inflectra for inpatient use.   Let me know if you have any questions. 

 

--

Richard Cramer, Pharm. D., FASHP, BCGP

Drug Information Coordinator






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved